This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.
PRIMARY OBJECTIVES: I. To create a comprehensive registry that includes patient demographics, clinical and histopathological data, blood samples, and tissue specimens from the primary tumor and metastatic sites of patients with metastatic breast cancer to improve our understanding of the mechanisms of tumor metastasis and therapeutic resistance. II. To conduct genomic studies of paired primary tumors and distant metastatic sites. III. To conduct genomic studies of paired distant metastatic sites obtained during the course of an individual's disease. IV. To conduct genomic studies of cell free deoxyribonucleic acid (DNA), circulating tumor cell (CTC) derived DNA, germline DNA, and immune based markers in the peripheral circulation. SECONDARY OBJECTIVE: I. To evaluate the concordance between DNA sequencing results obtained from a clinically available assay and those obtained specifically for research purposes. OUTLINE: Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
Study Type
OBSERVATIONAL
Enrollment
300
Undergo biospecimen collection
Undergo clinical information collection
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
UCSF Medical Center-Mission Bay
San Francisco, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
...and 4 more locations
Comprehensive biorepository creation
Will create a comprehensive biorepository that includes blood, archival tissue, fresh tissue, and linked molecular and clinical data from patients with recurrent and/or metastatic breast cancer.
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.